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Running title 37 





Lascufloxacin showed potent activity against Streptococcus pneumoniae with GyrA or 41 
ParC mutation (first-step mutants). The frequency to select resistant strains tended to be 42 
lower in lascufloxacin than in levofloxacin and garenoxacin after drug exposure of 43 
first-step mutants, whereas that was similar in the comparison between lascufloxacin 44 
and moxifloxacin. The MIC increase was smaller for lascufloxacin than levofloxacin, 45 
garenoxacin, and moxifloxacin when clinical strains with only ParC mutation were 46 
exposed to the corresponding drug. 47 
 48 




Fluoroquinolones inhibit DNA synthesis by binding to DNA gyrase (GyrA, GyrB) and 51 
topoisomerase IV (ParC, ParE) in Streptococcus pneumoniae (1). Fluoroquinolone 52 
resistance is usually due to gradual accumulation of GyrA and ParC mutations in the 53 
quinolone resistance-determining regions (QRDRs) (1, 2). Previously, we reported that 54 
either GyrA or ParC mutation (first-step) was detected in 20 (48.8%) of 41 susceptible 55 
strains with levofloxacin MICs of 1 or 2 µg/mL (3, 4). Several in vitro studies and a 56 
case report indicated that second-step mutants with both GyrA and ParC mutations 57 
could be selected on exposure of first-step mutants to fluoroquinolones (5 – 7). 58 
Lascufloxacin was newly developed by Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan) 59 
as a respiratory fluoroquinolone. We evaluated the in vitro activity of lascufloxacin 60 
against S. pneumoniae, focusing on the selectivity of resistant strains after drug 61 
exposure of first-step mutants. 62 
We used clinical isolates from patients in Japan between January 2006 and December 63 
2008 for MIC measurement (3). The MICs were measured using the broth microdilution 64 
method with MIC plates customized by Eiken Chemical Co., Ltd. (Tokyo, Japan) 65 
according to the Clinical and Laboratory Standard Institute (CLSI) protocol. Susceptible 66 
strains with levofloxacin MICs of ≤ 2 µg/mL were chosen, and 33 clinical isolates were 67 
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included in this study. The MIC90 of lascufloxacin was 0.12 μg/mL (Table 1). Mutations 68 
in the QRDRs were detected by pyrosequencing. DNA was extracted using the boiling 69 
method reported previously with minor modifications (8). PCR amplification for 70 
pyrosequencing was performed according to the following profile: 4 minutes at 94°C, 71 
50 cycles consisting of 15 s at 94°C, 15 s at 55°C, and 20 s at 72°C, with a final 72 
extension step of 5 minutes at 72°C. Primers for gyrA reverse and parC forward had a 73 
5'-biotin label (Bio). PCR primers were as follows: gyrA forward, 74 
5'-GAATGAATTGGGTGTGAC-3'; gyrA reverse, 75 
5'-Bio-ATACGTGCCTCGGTATAA-3'; parC forward, 76 
5'-Bio-GTTCAACGCCGTATTCTT-3'; parC reverse, 77 
5'-TGCCTCAGTATAACGCATAG-3' (9). We evaluated the presence of mutations by 78 
pyrosequencing using PyroMark ID (Biotage, Uppsala, Sweden) according to the 79 
manufacturer’s instructions. Primers for pyrosequencing were as follows: gyrA, 80 
5'-GGTAAATACCACCCACACGG-3'; parC, 5'-CTGTGACATACGAACCAT-3' (3, 81 
10). Of the 33 strains, 14 strains (42.4%) had a mutation in ParC, whereas no strains 82 
with only GyrA mutation were found. The MICs of lascufloxacin and levofloxacin for 83 
first-step mutants were 0.06 – 0.12 μg/mL and 2 μg/mL, respectively. 84 
To determine the frequency of the appearance of resistant strains after fluoroquinolone 85 
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exposure, we used four clinical isolates (G21, G27, G39, and G11) selected from the 86 
strains described above, and four laboratory strains (NF9884, CF9842, SF9863, and 87 
GF9821) with a first-step QRDR mutation (11). IID553 (wild-type) was used as a parent 88 
strain of the first-step laboratory strains. We measured the MICs of levofloxacin, 89 
garenoxacin, moxifloxacin, and lascufloxacin using the agar dilution method according 90 
to the CLSI protocol. Lascufloxacin and garenoxacin were provided by Kyorin 91 
Pharmaceutical Co., Ltd., and levofloxacin and moxifloxacin were purchased from 92 
Sigma-Aldrich Japan (Tokyo, Japan) and Tokyo Chemical Industry Co., Ltd. (Tokyo, 93 
Japan), respectively. Bacteria were incubated at 35°C for 3 days on Mueller Hinton II 94 
agar (Becton Dickinson, Franklin Lakes, NJ) with 5% defibrinated sheep blood (Nippon 95 
Bio-Test Laboratories Inc., Tokyo, Japan) containing fluoroquinolones at 2×, 4×, 8×, 96 
and 16×MICs. The frequency of the appearance of resistant strains was calculated as the 97 
ratio of the number of colonies that appeared to that of bacteria inoculated (12). No 98 
differences were observed in the frequency of the appearance of resistant strains when 99 
the wild-type laboratory strain, IID553, was exposed to lascufloxacin, levofloxacin, and 100 
garenoxacin. The similar result was seen in the comparisons between lascufloxacin and 101 
moxifloxacin. Conversely, the frequencies of resistance to lascufloxacin tended to be 102 
lower than those to levofloxacin and garenoxacin in both laboratory and clinical strains 103 
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with first-step mutations (Table 2a). Those to lascufloxacin were similar to those to 104 
moxifloxacin (Table 2b). Additionally, although the MICs of levofloxacin, garenoxacin, 105 
and moxifloxacin for strains selected after exposure of the clinical strains with only 106 
ParC mutation to the corresponding drug were increased up to 16-, 32-, and 16-fold, 107 
respectively, those of lascufloxacin were increased up to fourfold, compared with the 108 
parent strains (Table 3a and Table 3b). These results indicated that lascufloxacin was 109 
unlikely to result in the development of resistance in first-step mutants. 110 
It was reported that gatifloxacin, clinafloxacin, and sitafloxacin, which inhibited both 111 
DNA gyrase and topoisomerase IV, had lower propensities to select resistant strains (12 112 
– 14). The slight increases in the MICs of lascufloxacin in selected second-step mutants 113 
also suggested that lascufloxacin possessed dual target properties against both target 114 
enzymes in first-step mutants. On the other hand, if resistant strains were selected on 115 
exposure of clinical strains with only ParC mutation to the corresponding drug, the 116 
increases in MICs of lascufloxacin were smaller than those of levofloxacin and 117 
garenoxacin, and moxifloxacin. These observations suggested that lascufloxacin has 118 
high potency against mutated DNA gyrase and topoisomerase IV. Taken together, the 119 
stable activity of lascufloxacin against first- and second-step mutants of S. pneumoniae 120 
was thought to be due to the dual target properties and inhibition of the mutated 121 
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enzymes. A recent study indicated that lascufloxacin showed strong activity against S. 122 
pneumoniae, including fluoroquinolone-resistant strains, and enzymatic analysis 123 
indicated that lascufloxacin showed potent inhibitory activities against DNA gyrase and 124 
topoisomerase IV with mutation in Staphylococcus aureus as well as against those 125 
without mutations (15). This report was consistent with our proposal regarding the 126 
activity of lascufloxacin. 127 
No additional mutations were observed in some of the strains selected by exposure to 128 
fluoroquinolones (Table 3a and Table 3b 村田さんの結果確認). Although gradual 129 
accumulation of GyrA and ParC mutations was the main cause of fluoroquinolone 130 
resistance, the increases in MICs in those strains were thought to be due to other 131 
mechanisms, such as GyrB and ParE mutations and overexpression of efflux pumps, 132 
including PmrA and PatA/PatB ABC transporter (16, 17). 133 
Lascufloxacin showed potent activity against first-step mutants. In addition, 134 
lascufloxacin was unlikely to select resistant strains after drug exposure of first-step 135 
mutants compared with levofloxacin and garenoxacin. The selectivity of resistant strains 136 
from first-step mutants was similar in the comparison between lascufloxacin and 137 
moxifloxacin. We cannot distinguish first-step mutants based on drug susceptibility 138 
because they may be susceptible according to the current CLSI breakpoint MIC (≤ 2 139 
9 
 
µg/mL) for levofloxacin. Lascufloxacin would contribute to preventing the emergence 140 
of resistance when treating pneumococcal infections in clinical settings. A clinical trial 141 
is currently in progress in Japan, and further clinical studies will clarify the efficacy of 142 




Reagents (lascufloxacin and garenoxacin), technical support, and funding were 145 
provided by Kyorin Pharmaceutical Co., Ltd. This work was partly presented as a poster 146 
at ASM Microbe 2016. This study was partially supported by the Health and Labour 147 
Sciences Research Grants from Ministry of Health, Labour and Welfare, Japan 148 
(H28-Shinkou-Ippan-003) and a grant for Research and development of diagnostic 149 
methods and therapies for antimicrobial resistant bacteria from Japan Agency for 150 




1. Cornick JE, Bentley SD. 2012. Streptococcus pneumoniae: the evolution of 153 
antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. 154 
Microbes Infect 14:573-583. 155 
2. Brueggemann AB, Coffman SL, Rhomberg P, Huynh H, Almer L, Nilius A, 156 
Flamm R, Doern GV. 2002. Fluoroquinolone Resistance in Streptococcus 157 
pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 158 
46:680-688. 159 
3. Araki N, Yanagihara K, Matsukawa Y, Harada Y, Migiyama Y, Nagaoka K, 160 
Yamada K, Morinaga Y, Hasegawa H, Kohno S, Kamihira S. 2013. Molecular 161 
characterization of quinolone-insensitive Streptococcus pneumoniae isolates 162 
from Japanese patients. J Infect Chemother 19:356-359. 163 
4. CLSI. 2014. Performance standards for antimicrobial susceptibility testing; 164 
twenty-fourth informational supplements. CLSI document M100-S24. Clinical 165 
and Laboratory Standards Institute Wayne, PA. 166 
5. Yamamoto K, Yanagihara K, Sugahara K, Imamura Y, Seki M, Izumikawa K, 167 
Kakeya H, Yamamoto Y, Hirakata Y, Kamihira S, Kohno S. 2009. In vitro 168 
activity of garenoxacin against Streptococcus pneumoniae mutants with 169 
characterized resistance mechanisms. Antimicrob Agents Chemother 170 
53:3572-3575. 171 
6. Li X, Zhao X, Drlica K. 2002. Selection of Streptococcus pneumoniae Mutants 172 
Having Reduced Susceptibility to Moxifloxacin and Levofloxacin. Antimicrob 173 
Agents Chemother 46:522-524. 174 
7. de Cueto M, Rodriguez JM, Soriano MJ, Lopez-Cerero L, Venero J, Pascual A. 175 
2008. Fatal levofloxacin failure in treatment of a bacteremic patient infected 176 
with Streptococcus pneumoniae with a preexisting parC mutation. J Clin 177 
Microbiol 46:1558-1560. 178 
8. Motoshima M, Yanagihara K, Morinaga Y, Matsuda J, Sugahara K, Yamada Y, 179 
Kohno S, Kamihira S. 2010. Genetic diagnosis of community-acquired MRSA: 180 
a multiplex real-time PCR method for Staphylococcal cassette chromosome mec 181 
typing and detecting toxin genes. Tohoku J Exp Med 220:165-170. 182 
9. Fukushima KY, Hirakata Y, Sugahara K, Yanagihara K, Kondo A, Kohno S, 183 
Kamihira S. 2006. Rapid screening of topoisomerase gene mutations by a novel 184 
melting curve analysis method for early warning of fluoroquinolone-resistant 185 
Streptococcus pneumoniae emergence. J Clin Microbiol 44:4553-4558. 186 
12 
 
10. Davies TA, Yee YC, Goldschmidt R, Bush K, Sahm DF, Evangelista A. 2006. 187 
Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase 188 
genes among US levofloxacin-susceptible clinical isolates of Streptococcus 189 
pneumoniae from nine institutions (1999-2003). J Antimicrob Chemother 190 
57:437-442. 191 
11. Fukuda H, Kishii R, Takei M, Hosaka M. 2001. Contributions of the 8-methoxy 192 
group of gatifloxacin to resistance selectivity, target preference, and antibacterial 193 
activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 45: 194 
1649-1653. 195 
12. Kishii R, Takei M, Fukuda H, Hayashi K, Hosaka M. 2003. Contribution of the 196 
8-methoxy group to the activity of gatifloxacin against type II topoisomerases of 197 
Streptococcus pneumoniae. Antimicrob Agents Chemother 47:77-81. 198 
13. Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T. 2008. 199 
Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and 200 
sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to 201 
reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J 202 
Antimicrob Chemother 62:98-104. 203 
14. Pan XS, Fisher LM. 1998. DNA gyrase and topoisomerase IV are dual targets of 204 
clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents 205 
Chemother 42:2810-2816. 206 
15. Kishii R, Yamaguchi Y, Takei M. 2017. In vitro activities and spectrum of the 207 
novel fluoroquinolone, lascufloxacin (KRP-AM1977). Antimicrob Agents 208 
Chemother doi:10.1128/AAC.00120-17. 209 
16. Gill MJ, Brenwald NP, Wise R. 1999. Identification of an efflux pump gene, 210 
pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. 211 
Antimicrob Agents Chemother 43:187-189. 212 
17. Baylay AJ, Piddock LJ. 2015. Clinically relevant fluoroquinolone resistance due 213 
to constitutive overexpression of the PatAB ABC transporter in Streptococcus 214 
pneumoniae is conferred by disruption of a transcriptional attenuator. J 215 
Antimicrob Chemother 70:670-679. 216 
TABLE 1. MICs of 33 clinical isolates for seven fluoroquinolones 
Drug MIC range (μg/mL) MIC50 (μg/mL) MIC90 (μg/mL) 
Lascufloxacin 0.06 – 0.12 0.12 0.12 
Garenoxacin 0.03 – 0.25 0.12 0.12 
Sitafloxacin 0.06 – 0.12 0.06 0.12 
Moxifloxacin 0.12 – 0.5 0.25 0.5 
Levofloxacin 1 – 2 2 2 
Ciprofloxacin 1 – 8 4 4 
Pazufloxacin 2 – 8 4 8 
MICs were measured using the broth microdilution method. 
TABLE 2a. Frequencies of appearance of resistant strains after exposure of laboratory and clinical strains to lascufloxacin, levofloxacin, and garenoxacin 
Strain 
 
QRDR mutation Drug MIC (μg/mL) Frequency at the following drug concentration 
ParC GyrA  2 × MIC 4 × MIC 8 × MIC 16 × MIC 




Lascufloxacin 0.06 2.5×10–8 n.d. n.d. n.d. 
Levofloxacin 0.5 4.1×10–6 n.d. n.d. n.d. 





Lascufloxacin 0.12 n.d. n.d. n.d. n.d. 
Levofloxacin 1 3.7×10–7 1.5×10–7 1.8×10–7 3.2×10–8 





Lascufloxacin 0.06 n.d. n.d. n.d. n.d. 
Levofloxacin 1 6.8×10–8 1.3×10–8 n.d. n.d. 





Lascufloxacin 0.06 8.5×10–6 9.6×10–7 n.d. n.d. 
Levofloxacin 1 8.5×10–6 7.7×10–6 3.3×10–6 n.d. 





Lascufloxacin 0.06 6.8×10–8 n.d. n.d. n.d. 
Levofloxacin 1 8.3×10–8 1.1×10–7 6.8×10–8 n.d. 
Garenoxacin 0.12 8.5×10–6 n.d. n.d. n.d. 
Clinical strains G21 S79F None Lascufloxacin 0.12 6.3×10–8 n.d. n.d. n.d. 
Levofloxacin 2 1.4×10–7 1.4×10–8 n.d. n.d. 
Garenoxacin 0.06 1.9×10–7 1.1×10–7 n.d. n.d. 
G27 S79F None Lascufloxacin 0.12 8.1×10–8 n.d. n.d. n.d. 
Levofloxacin 1 4.6×10–7 2.4×10–7 2.3×10–8 n.d. 
Garenoxacin 0.06 3.7×10–7 1.0×10–7 7.0×10–8 n.d. 
G39 D83V None Lascufloxacin 0.12 n.d. n.d. n.d. n.d. 
Levofloxacin 2 n.d. n.d. n.d. n.d. 
Garenoxacin 0.06 1.2×10–8 5.8×10–9 n.d. n.d. 
G11 D83Y None Lascufloxacin 0.12 n.d. n.d. n.d. n.d. 
Levofloxacin 2 3.7×10–8 n.d. n.d. n.d. 
Garenoxacin 0.06 1.3×10–7 3.7×10–8 n.d. n.d. 
 
TABLE 2b. Frequencies of appearance of resistant strains after exposure of laboratory and clinical strains to lascufloxacin and moxifloxacin 
Strain 
 
QRDR mutation Drug MIC (μg/mL) Frequency at the following drug concentration 
ParC GyrA  2 × MIC 4 × MIC 8 × MIC 16 × MIC 
Laboratory strains IID553 None None Lascufloxacin 0.06 n.d. n.d. n.d. n.d. 
  Moxifloxacin 0.12 n.d. n.d. n.d. n.d. 
NF9884 S79Y None Lascufloxacin 0.12 n.d. n.d. n.d. n.d. 
  Moxifloxacin 0.25 7.0 × 10–8 n.d. n.d. n.d. 
CF9842 D83N None Lascufloxacin 0.06 n.d. n.d. n.d. n.d. 
  Moxifloxacin 0.25 8.1 × 10–8 n.d. n.d. n.d. 
SF9863 None S81F Lascufloxacin 0.06 1.3 × 10–6 n.d. n.d. n.d. 
  Moxifloxacin 0.5 2.2 × 10–7 n.d. n.d. n.d. 
GF9821 None S81Y Lascufloxacin 0.06 2.6 × 10–7 n.d. n.d. n.d. 
  Moxifloxacin 0.5 2.0 × 10–7 n.d. n.d. n.d. 
Clinical strains G21 S79F None Lascufloxacin 0.12 n.d. n.d. n.d. n.d. 
  Moxifloxacin 0.25 n.d. n.d. n.d. n.d. 
G27 S79F None Lascufloxacin 0.12 n.d. n.d. n.d. n.d. 
  Moxifloxacin 0.25 1.3 × 10–7 n.d. n.d. n.d. 
G39 D83V None Lascufloxacin 0.12 n.d. n.d. n.d. n.d. 
  Moxifloxacin 0.25 1.3 × 10–8 n.d. n.d. n.d. 
G11 D83Y None Lascufloxacin 0.12 n.d. n.d. n.d. n.d. 
  Moxifloxacin 0.5 n.d. n.d. n.d. n.d. 
QRDR, quinolone resistance-determining region; n.d., not detected. 
MICs were measured using the agar dilution method. 
TABLE 3a. MICs of selected strains and additional mutation after exposure to lascufloxacin, levofloxacin, and garenoxacin 
Parent strain Exposure MIC (μg/mL) QRDR mutation 
Drug Concentration Lascufloxacin Levofloxacin Garenoxacin ParC GyrA 
G21 - - 0.12 2 0.06 S79F None 
Lascufloxacin 2 × MIC 0.25 16 0.5 S79F S81Y 
Levofloxacin 2 × and 4 × MIC 0.25 16 0.5 S79F S81Y 
Garenoxacin 2 × MIC 0.12 4 0.5 S79F None 
Garenoxacin 4 × MIC 0.25 16 0.5 S79F S81Y 
G27 - - 0.12 2 0.06 S79F None 
Lascufloxacin 2 × MIC 0.25 32 1 S79F E85K 
Lascufloxacin 2 × MIC 0.5 16 0.06 S79F None 
Levofloxacin 4 × MIC 0.5 32 0.12 S79F None 
Levofloxacin 8 × MIC 0.25 32 1 S79F E85K 
Garenoxacin 2 × MIC 0.12 2 0.5 S79F None 
Garenoxacin 8 × MIC 0.25 32 2 S79F E85K 
G39 - - 0.12 2 0.06 D83V None 
Garenoxacin 2 × MIC 0.12 8 0.5 D83V E85K 
Garenoxacin 4 × MIC 0.25 8 0.5 D83V S81F 
G11 - - 0.12 2 0.12 D83Y None 
Levofloxacin 2 × MIC 0.25 16 1 D83Y S81F 
Garenoxacin 2 × MIC 0.12 2 0.5 D83Y None 
Garenoxacin 4 × MIC 0.25 16 1 D83Y S81F 
TABLE 3b. MICs of selected strains and additional mutation after exposure to moxifloxacin 
Parent strain Exposure MIC (μg/mL) QRDR mutation 
Drug Concentration Lascufloxacin Levofloxacin Garenoxacin Moxifloxacin ParC GyrA 
G27 - - 0.12 2 0.06 0.25 S79F None 
Moxifloxacin 2 × MIC 0.25 16 0.12 2 S79F None 
Moxifloxacin 2 × MIC 0.25 16 1 4 S79F S81F 
G39 - - 0.12 2 0.06 0.25 D83V None 
Moxifloxacin 2 × MIC 0.25 8 0.5 2 D83V S81F 
QRDR, quinolone resistance-determining region. 
MICs were measured using the agar dilution method. 
